Robinj Effron News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Introduction
Pleading requirements in federal courts, particularly in securities class action cases, have become increasingly difficult, if not impossible, to satisfy. On December 30, 2020, a U.S. district court in California granted the motion of the biopharmaceutical company, Nektar Therapeutics, Inc. (“Nektar” or “Company”)
1 and its named officers (collectively, “Defendants”) to dismiss Plaintiffs’ second-amended securities fraud complaint (“Complaint”) by means of an opinion that stretched, we believe, well beyond the applicable pleading rules and statutes. Being the second dismissal in the case, the court denied Plaintiffs representatives of a putative class of shareholders of Nektar stock a third chance to amend their Complaint. ....

United States , San Francisco , Angelica Lavito , Robinj Effron , Bristol Myers Squibb , Tellabs Inc , Exchange Act Section , American Society Of Clinical Oncology , Us Court , Bristol Myers Squibb Company , Bristol Myers Squibb Co , Nektar Or Company , Nektar Therapeutics Inc , Society For Immunotherapy Of Cancer , Supreme Court , Us Supreme Court , District Court Pleading Standards In Nektar , Makor Issues Rights Ltd , Securities Exchange , Nektar Therapeutics , Federal Rules , Civil Procedure , Anti Cancer Drug , Healthcare Conference , Private Securities Litigation Reform Act , Securities Exchange Act ,